All News

How the DIA, a key industry NGO, is repositioning itself as the go-to place for the independent knowledge-driven insights that drive decisions in a business with no boundaries. One world. One table. Open seating.

Altruism and self-interest are at the heart of European thinking on neglected diseases.

The practice’s emerging-if improbable-cost-saving potential.

Click the title above to open the Pharmaceutical Executive April 2016 issue in an interactive PDF format.

Europe’s contrasting views on rare disease drugs - one bashing pricing abuses, the other extolling their public health virtues - could ultimately leave these products out in the cold.

Click the title above to open the Pharmaceutical Executive March 2016 issue in an interactive PDF format.

As US pharma continues to ponder its “winter of discontent”, the question that leaders of industry have to be asking themselves is, “How did things get this bad?” Tom Norton reports.

Defending pharma and health direct-to-consumer advertising is a top 2016 priority for the 4A’s industry trade group.

Click the title above to open the Pharmaceutical Executive February 2016 issue in an interactive PDF format.

Harvard Business School has launched a competition to generate ideas to bring precision diagnostics and therapies to market more quickly by reinventing the clinical trials process.

Casey McDonald keeps an eye on the one of the healthcare industry’s biggest weeks on Twitter with regular updates here.

The continuing attack on industry pricing and marketing jeopardizes coverage, R&D.

Click the title above to open the Pharmaceutical Executive January 2016 issue in an interactive PDF format.

The continuing campaign to ratchet down prescription drug prices has generated considerable talk about how compounders could provide less costly, alternative therapies. Jill Wechsler reports.